Bioventus Inc

Stage 2’s advancing corrective reset remains intact, driven by an active Lockout Rally that has propelled price above rising 9/21 EMAs on expanding volume. Despite extreme overbought readings, forced participation dynamics justify immediate entry to capture the ongoing breakout leg. We recommend buying now to participate in the continuation.

• ↑Q1 2026 revenue reached $132M, up 7% YoY
• ↑Adjusted EBITDA rose 24% to $24M, margin expanded to 18%
• ↓Profitability score remains weak with high leverage at 1.05x